NuVasive Inks $14M FCA Deal Over Kickbacks, Off-Label Uses
Medical device maker NuVasive Inc. will pay $13.5 million to resolve whistleblower allegations that it violated the False Claims Act by promoting off-label uses of spinal fusion products for Medicare patients...To view the full article, register now.
Already a subscriber? Click here to view full article